PFE - Novavax Faces Setback European Authority Delays Decision On Variant-Tailored COVID-19 Vaccine | Benzinga
Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.
This delay comes at a challenging time for the US-listed biotech, grappling with declining demand for COVID-19 vaccines.
The EMA was set to approve the updated jab, but instead, they've requested more information, raising concerns about the vaccine's characteristics.
The EMA's questions center around the vaccine's potency and ensuring consistency across different production sites. The EMA ...